Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnWeb3SquareMore
Trade
Spot
Buy and sell crypto with ease
Margin
Amplify your capital and maximize fund efficiency
Onchain
Going Onchain, without going Onchain!
Convert & block trade
Convert crypto with one click and zero fees
Explore
Launchhub
Gain the edge early and start winning
Copy
Copy elite trader with one click
Bots
Simple, fast, and reliable AI trading bot
Trade
USDT-M Futures
Futures settled in USDT
USDC-M Futures
Futures settled in USDC
Coin-M Futures
Futures settled in cryptocurrencies
Explore
Futures guide
A beginner-to-advanced journey in futures trading
Futures promotions
Generous rewards await
Overview
A variety of products to grow your assets
Simple Earn
Deposit and withdraw anytime to earn flexible returns with zero risk
On-chain Earn
Earn profits daily without risking principal
Structured Earn
Robust financial innovation to navigate market swings
VIP and Wealth Management
Premium services for smart wealth management
Loans
Flexible borrowing with high fund security
Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety

Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety

Bitget-RWA2025/10/24 12:32
By:Bitget-RWA

- Inhibrx Biosciences’ ozekibart showed 52% reduced disease progression risk in chondrosarcoma, driving a 70% post-market stock surge. - Combination trials in colorectal and Ewing sarcoma showed 23%–64% response rates, suggesting broader oncology potential. - Hepatotoxicity concerns led to monitoring strategies, reducing adverse events to 11.8% in ozekibart group. - Company plans 2026 BLA submission; stock surged 63% pre-market after prior 10% decline.

Shares of Inhibrx Biosciences (NASDAQ:INBX) soared by more than 70% in after-hours trading on October 23, 2025, after the company announced encouraging Phase 2 trial data for its investigational cancer therapy ozekibart (INBRX-109) in chondrosarcoma, a rare and aggressive bone malignancy that currently lacks approved systemic treatments, as reported by an

. The ChonDRAgon clinical trial, which compared ozekibart as a standalone treatment to placebo, achieved its main goal by showing a statistically significant 52% decrease in the risk of disease progression or death relative to the control group. Patients administered ozekibart experienced a median progression-free survival (PFS) of 5.52 months, more than twice the 2.66 months seen in those receiving placebo. Additionally, the drug achieved a disease control rate of 54% compared to 27.5% for placebo, with consistent positive outcomes across all predefined subgroups, according to .

Ozekibart’s safety profile was generally acceptable, though liver toxicity was identified as a significant issue. Early in the study, a fatal liver-related incident led to the adoption of risk mitigation strategies, including excluding patients with advanced liver dysfunction and closely monitoring liver function during the initial treatment cycles. These interventions reduced the rate of treatment-related liver side effects to 11.8% in the ozekibart group versus 4.5% in the placebo group, with most cases being mild or moderate in severity, as detailed in

.

Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety image 0

In addition to chondrosarcoma,

shared encouraging interim results from expansion cohorts evaluating ozekibart in combination regimens for colorectal cancer and Ewing sarcoma. Among heavily pretreated colorectal cancer patients, the combination of ozekibart with FOLFIRI chemotherapy resulted in a 23% overall response rate and a 92% disease control rate. For Ewing sarcoma, pairing ozekibart with irinotecan and temozolomide yielded a 64% overall response rate and a 92% disease control rate, as reported by Investing.com. These outcomes indicate that the therapy may have broader potential in oncology.

The company intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration in the second quarter of 2026, according to Investing.com. Comprehensive data from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025, as noted by Tokenist.

The market responded strongly to the announcement, with

shares climbing from $28.36 on October 23 to $46.30 in pre-market trading the next day—a 63.26% increase, according to Tokenist. This jump followed a 10% drop in the previous session, highlighting the volatility typical of biotech equities. Trading volume surged to 1.15 million shares, far above the average of 151,435, per Tokenist. Retail investors on platforms such as Stocktwits became "extremely bullish," with message activity rising by 985% in 24 hours, as tracked by .

Financially, Inhibrx has a market capitalization near $457 million and maintains strong liquidity, with a current ratio close to 5, according to

. However, the company posted a net loss of $28.65 million in the latest quarter, mainly due to substantial research and development spending, as reported by . Despite these losses, analysts see ozekibart as a potential revenue driver if it gains regulatory approval.

INBX shares have climbed 140% year-to-date, reflecting strong investor confidence, though some warn that commercial success will depend on overcoming regulatory challenges and proving long-term effectiveness. With no approved therapies for chondrosarcoma, ozekibart’s potential to be first to market has drawn parallels to other breakthrough drugs in specialized oncology fields, according to Stocktwits.

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!

You may also like

AI’s Risky Bet on Volatility Fails: 80% Plunge Reveals Market’s Heavy Dependence

- Alpha Arena's report reveals 80% capital loss in AI-driven trading models, exposing algorithmic strategy flaws amid market volatility. - BigBear.ai faces 18% revenue decline and $90M operating loss due to Trump-era spending cuts, despite defense tech partnerships. - C3.ai struggles with CEO departure, legal disputes, and 50% stock drop, contrasting UiPath's 14% AI-powered revenue growth and 108% retention rate. - Market skepticism grows as AI volatility risks emerge, with quantum computing still distant

Bitget-RWA2025/10/24 15:54

Bitcoin News Update: Institutions Invest $314 Million in Bitcoin as Bull Market Targets $115,000

- Bitcoin approaches $115k as RUL drops below 5%, signaling strong long-term holder confidence. - Institutions like BlackRock deposit $314M BTC/ETH into Coinbase, while Fed explores crypto payment accounts. - ETF inflows favor Bitcoin over Ethereum, but derivatives hedging and macro risks pose breakout challenges. - Technical indicators show consolidation with elevated open interest, awaiting regulatory clarity for next moves.

Bitget-RWA2025/10/24 15:54
Bitcoin News Update: Institutions Invest $314 Million in Bitcoin as Bull Market Targets $115,000

Cardano News Today: Cardano's $0.62 at a Critical Point: Bulls Eye $2.96, Bears Aim for $0.50

- Cardano (ADA) faces a 20% monthly decline near $0.64, with analysts divided on its potential for a bullish breakout or further losses. - A critical $0.63–$0.64 support defense could trigger a 333% surge to $2.96, while a breakdown below $0.62 risks a drop to $0.50. - Whale accumulation of 200M ADA tokens and stable market cap ($22–$25B) contrast with broader crypto market weakness affecting ADA, Bitcoin, and Ethereum. - Short-term momentum indicators show improved buying pressure above $0.67–$0.68, but f

Bitget-RWA2025/10/24 15:38
Cardano News Today: Cardano's $0.62 at a Critical Point: Bulls Eye $2.96, Bears Aim for $0.50

Healthcare organizations resolve privacy litigation to mitigate risks amid increased examination of tracking technologies

- Pomona Valley Hospital settles $600,000 lawsuit over unauthorized Facebook Pixel tracking on its website, alleged to violate California privacy laws. - The class-action, filed in 2023, claimed the hospital illegally intercepted user data via tracking tools during patient portal logins between 2019-2022. - Settlement terms include pro-rata payments to affected California residents, with funds covering legal fees and administrative costs, though the hospital denies wrongdoing. - The case reflects heightene

Bitget-RWA2025/10/24 15:38
Healthcare organizations resolve privacy litigation to mitigate risks amid increased examination of tracking technologies